Eris Lifesciences hits an all-time high on the back of strong Q2 results; here's what Anil Singhvi says about it
The stock of the pharma company was trading higher by 3.99 per cent, or Rs 35.80, at Rs 933.40 on Thursday.
Eris Lifesciences is buying dermatology and nephrology branded formulation businesses from Biocon Biologics for Rs 366 crore. Photo: Eris Lifesciences/Representational